Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model ...

Chicago Partners Investment Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

I worked closely with NCI’s Investigational Drug Branch (IDB) from 1990-2016, including as a principal investigator of one of ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) yesterday and set a ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known consensus ...

The equity market in 2025 so far has been characterized by heightened volatility, primarily driven by escalating geopolitical tensions and renewed trade conflicts. Trump's aggressive tariff policies ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to highlight recent corporate ...